Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844105 | 1.00 | CYP1A2 (0.44) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL31047922 | 0.91 | CYP1A2 (0.40) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL949804 | 0.86 | CYP1A2 (0.45) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL31098592 | 0.86 | CYP1A2 (0.45) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL12359170 | 0.86 | CYP1A2 (0.49) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL948907 | 0.84 | CYP1A2 (0.44) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL14686051 | 0.84 | CYP1A2 (0.44) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL23970505 | 0.82 | CYP4F2 (0.40) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL30411259 | 0.82 | CYP4F2 (0.40) | CYP1A2HPGDSGABRA1GABRG2GABRB3 | |
| SCHEMBL1181244 | 0.82 | MAPT (0.51) | CYP1A2MRGPRX4BRD4MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137822-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | ABDERA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-07-10 | — | — | US | disclosed |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | Abdera Therapeutics Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4267205-B1 | BISPIDINE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ ZENTRUM DRESDEN (DE) | 2025-02-19 | — | — | EP | disclosed |
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. | 2025-02-13 | — | — | US | disclosed |
| US-20240285817-A1 | BISPIDINE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2024-08-29 | — | — | US | disclosed |
| US-20240207462-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (CA) | 2024-06-27 | — | — | US | disclosed |
| US-20240174622-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| WO-2024044554-A1 | VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044550-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-2536691-B1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-11-22 | — | — | EP | disclosed |
| EP-2536691-B1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-11-22 | — | — | EP | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| EP-2536691-A1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc. (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011100829-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. (CA) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | DLK1, DBNL, DVL3 | CYP1A2 4882/4885HPGDS 2130/4885GABRA1 614/4885 |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | DLK1, CD2BP2, IGLV6-57 | CYP1A2 4851/4885HPGDS 3394/4885GABRA1 825/4885 |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | PAICS, RABGGTB, PARP1 | CYP1A2 4390/4885HPGDS 1324/4885GABRA1 3367/4885 |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | FCGRT, C1QBP, H1-2 | CYP1A2 2997/4885HPGDS 1560/4885GABRA1 2897/4885 |
| US-20240285817-A1 | BISPIDINE DERIVATIVES AND THE USE THEREOF | NISCH, RAB9A, TUBB2B | CYP1A2 265/4885HPGDS 3790/4885GABRA1 319/4885 |
| US-20240207462-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | FCGR2A, FCGR3B, CD74 | CYP1A2 4291/4885HPGDS 1897/4885GABRA1 601/4885 |
| US-20260137822-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | FCGR2A, FCGR3B, FCGR1A | CYP1A2 4055/4885HPGDS 4664/4885GABRA1 1923/4885 |
| US-20240174622-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | PSMA2, PSMA1, PSMA3 | CYP1A2 4182/4885HPGDS 3070/4885GABRA1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.